Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

A new research paper was published in , Volume 16, on April 24, 2025, titled "PD-L1 and FOXP3 expression in high-grade squamous intraepithelial lesions of the anogenital region." ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Stacey Davis appointed as Chief Business Officer and Chief Financial Officer Clive Wood, Ph.D. joins Enara Board as ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Although recommended, many patients with metastatic clear cell RCC still don’t receive immune checkpoint inhibitor-based combinations as first-line treatment.